Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...
Mereo BioPharma: Good Science, Fairly Valued
Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.
The Pharma Letter15d
Ultragenyx updates on UX111 AAV gene therapy
California, USA-based rare disease company Ultragenyx Pharmaceutical (Nasdaq: RARE) yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a ...
Investing15d
Ultragenyx reports positive data on gene therapy for rare disease
Goldman Sachs, maintaining a Buy rating on Ultragenyx, has expressed confidence in the company's Phase 3 Orbit study of setrusumab for osteogenesis imperfecta. The firm also anticipates further ...
Investing16d
Ultragenyx reports positive data on gene therapy for rare disease
Goldman Sachs, maintaining a Buy rating on Ultragenyx, has expressed confidence in the company's Phase 3 Orbit study of setrusumab for osteogenesis imperfecta. The firm also anticipates further ...